Sinovac Biotech
科兴生物
Executive Summary
Sinovac Biotech is a Beijing-based vaccine developer best known for its COVID-19 vaccine CoronaVac, which achieved global distribution including emergency use authorizations. The company has established manufacturing capabilities and regulatory experience across multiple markets, making it an attractive partner for vaccine development and manufacturing deals. With clear BIOSECURE status, Sinovac presents lower regulatory risk for US partnerships compared to many Chinese biotech peers. The company has historically been open to licensing and partnership arrangements, particularly for global market access.
Structure: Sinovac operates as a NASDAQ-listed Chinese biotech with typical VIE structure for foreign investment compliance. The company maintains operating subsidiaries in China while being incorporated offshore for US listing purposes. Due diligence should focus on the VIE agreements and any recent structural changes given evolving Chinese regulations on foreign listings.
BIOSECURE Risk
Company has clear BIOSECURE status with no current designation, and vaccine manufacturing is generally viewed as less sensitive than other biotech sectors
Key Exposures:
- •US-listed Chinese company subject to potential future policy changes
- •VIE structure regulatory evolution
- •General US-China trade tensions
Mitigation: Maintaining compliance with US listing requirements and has not been flagged by US regulatory authorities
BD Intelligence
Therapeutic Areas:
Recent Deals: Limited recent public deal activity; historically focused on manufacturing partnerships and regional licensing
Approach: Approach through established channels focusing on manufacturing partnerships, regional licensing, or vaccine platform collaborations
Red Flags
- ⚠Limited recent corporate event visibility
- ⚠Management team information gap
- ⚠Post-COVID vaccine market positioning unclear
- ⚠Potential VIE structure regulatory changes
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.